Asset Details
Do you wish to reserve the book?
Reduced-intensity, standard conditioning demonstrate comparable transplant outcomes in myelodysplastic syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reduced-intensity, standard conditioning demonstrate comparable transplant outcomes in myelodysplastic syndrome
Do you wish to request the book?
Reduced-intensity, standard conditioning demonstrate comparable transplant outcomes in myelodysplastic syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reduced-intensity, standard conditioning demonstrate comparable transplant outcomes in myelodysplastic syndrome
2017
Overview
A reduced-intensity conditioning regimen yielded comparable RFS and OS as standard myelo ablative conditioning among patients with myelodysplastic syndrome, according to results of the phase 3 RICMAC clinical trial. Reduced-intensity conditioning also improved OS (HR = 0.41; 95% CI, 0.19-0.87). Because the results of the RICMAC trial are based on the standard therapy of busulfan/cyclophosphamide - which is linked to higher transplant-related mortality - more data are needed, Michael A. Pulsipher, MD, section head of blood and marrow transplantation at Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, wrote in a related editorial. Would a young, high-risk patient with MDS with an HLA-identical sibling be entered on this study or simply proceed with a myeloablative transplant? Because the precise criteria for HSCT are not defined, might patients at low risk for relapse undergoing transplantation on this trial diminish the potential relapse-lowering advantage of myeloablation?
Publisher
SLACK INCORPORATED
Subject
